60 DEGREES PHARMACEUTICALS, INC.
SXTPNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | $1.0M | $607,574 | $253,573 | $223,208 |
| Operating income | −$7.8M | −$9.7M | −$5.2M | −$1.8M |
| Net income | −$7.4M | −$7.9M | −$3.8M | −$6.2M |
| Total assets | $5.4M | $5.8M | $7.8M | $1.3M |
| Total liabilities | $2.0M | $1.8M | $3.0M | $25.4M |
| Equity | $3.5M | $4.0M | $4.9M | −$23.6M |
| EPS (diluted) | $-11.73 | $-74.17 | $-0.99 | $-2.61 |
| Shares out. | 1.5M | 11.6M | 96,847 | 2.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −771.6%
- Net margin
- −732.5%
- Return on equity
- −212.7%
- Return on assets
- −137.3%
- Return on capital (ROCE)
- −220.2%
- Liabilities / assets
- 37.0%
- Debt / equity
- 0.57×
- Book value / share
- $2.35
- Revenue growth (YoY)
- 65.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -33.25distress
- Accruals / assets
- −9.6%clean
- Beneish M-Score
- -2.39normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2027-02B-FREE Chronic Babesiosis Study
- Phase 2Recruitingreadout ~2027-03-01Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Cvi Investments, Inc.Passive (13G)May 15, 2026
- Knight Therapeutics Inc.Passive (13G)May 15, 2026
- Intracoastal Capital, LlcPassive (13G)May 13, 2026
- Ayrton Capital LlcPassive (13G)Nov 13, 2025
- Orca Capital AgPassive (13G)Jul 17, 2025
- Armistice Capital, LlcPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 141,535 | 2.5 | -0.8% |
| Apr 30, 2026 | 142,704 | 1.5 | -21.7% |
| Apr 15, 2026 | 182,287 | 1.0 | +13.4% |
| Mar 31, 2026 | 160,681 | 1.0 | -66.8% |
| Mar 13, 2026 | 484,774 | 1.0 | +402.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 18, 2026
- Other material eventMar 20, 2026
- Other material eventMar 13, 2026
- Other material eventMar 12, 2026
- Other material eventFeb 12, 2026
- Delisting / listing-standard notice · Regulation FD disclosureJan 23, 2026
- Amended charter or bylaws · Other material eventJan 21, 2026
- Regulation FD disclosureJan 8, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 3May 19, 2026
- 8-KCURRENT REPORTMay 18, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 15, 2026
- SCHEDULE 13G/AMay 13, 2026
- 10-KMar 30, 2026
- 8-KCURRENT REPORTMar 20, 2026
- 424B5PROSPECTUS SUPPLEMENTMar 13, 2026
- 8-KCURRENT REPORTMar 13, 2026
- 8-KCURRENT REPORTMar 12, 2026
- 424B5PROSPECTUS SUPPLEMENTMar 11, 2026
- 424B5PROSPECTUS SUPPLEMENTMar 2, 2026
- 8-KCURRENT REPORTFeb 12, 2026
- 8-KCURRENT REPORTJan 23, 2026